肠道菌群及其代谢物与非酒精性脂肪性肝病

Intestinal Flora and Its Metabolites and Nonalcoholic Fatty Liver Disease

总结相关的实验研究发现,人体肠道菌群是非酒精性脂肪性肝病(NAFLD)发生发展的关键因素,除了人体肠道菌群组成的变化外,肠道菌群的代谢物也成为调节NAFLD病理过程的关键因素;有研究发现,肠道菌群的代谢物如短链脂肪酸、胆汁酸、三甲胺和乙醇等通过肠-肝轴途径影响肝脏代谢功能,从而导致疾病发生。现从NAFLD患者肠道菌群和代谢物的变化及发病机制,总结并探讨通过调节肠道菌群及其代谢物来治疗NAFLD,期望这些治疗策略会成为未来优化治疗NAFLD等代谢性肝病的有效方法。

Summary of relevant experimental studies found that the human intestinal flora is a key factor in the development of non-alcoholic fatty liver disease(NAFLD).In addition to changes in the composition of human intestinal flora,the metabolites of intestinal flora also become the key factors regulating the pathological process of NAFLD.Some studies have found that metabolites of intestinal flora such as short-chain fatty acids,bile acids,trimethylamine and ethanol affect liver metabolic function through the gut-liver axis pathway,thus leading to disease.Based on the changes and pathogenesis of intestinal flora and metabolites in patients with NAFLD,this paper summarizes and discusses the treatment of NAFLD by regulating intestinal flora and metabolites,hoping that these therapeutic strategies will become effective ways to optimize the treatment of metabolic liver diseases such as NAFLD in the future.